{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:44:21Z","timestamp":1776437061711,"version":"3.51.2"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Osteoporosis is a chronic condition that reflects reduced bone strength and an associated increased risk for fracture. As a chronic condition, osteoporosis generally requires sustained medical intervention(s) to limit the risks for additional bone loss, compromise of skeletal integrity, and fracture occurrence. Further complicating this issue is the fact that the abrupt cessation of some therapies can be associated with an increased risk for harm. It is in this context that the COVID-19 pandemic has brought unprecedented disruption to the provision of health care globally, including near universal requirements for social distancing. In this Perspective, we provide evidence, where available, regarding the general care of patients with osteoporosis in the COVID-19 era and provide clinical recommendations based primarily on expert opinion when data are absent. Particular emphasis is placed on the transition from parenteral osteoporosis therapies. It is hoped that these recommendations can be used to safely guide care for patients with osteoporosis until a return to routine clinical care standards is available. \u00a9 2020 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.4049","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T12:20:52Z","timestamp":1589458852000},"page":"1009-1013","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Osteoporosis Management in the Era of COVID-19"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-0839","authenticated-orcid":false,"given":"Elaine W","family":"Yu","sequence":"first","affiliation":[{"name":"Endocrine Unit Massachusetts General Hospital\/Harvard Medical School Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"Center for Healthy Aging Universit\u00e4tsklinikum Dresden Dresden Germany"},{"name":"Department of Medicine III Universit\u00e4tsklinikum Dresden Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-9546","authenticated-orcid":false,"given":"Bart L","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-7721","authenticated-orcid":false,"given":"Douglas C","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco CA USA"},{"name":"Department of Medicine University of California, San Francisco San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-7345","authenticated-orcid":false,"given":"Matthew T","family":"Drake","sequence":"additional","affiliation":[{"name":"Robert and Arlene Kogod Center on Aging Mayo Clinic Rochester MN USA"},{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"issue":"10223","key":"2024031418592112100_jbmr4049-bib-0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"2024031418592112100_jbmr4049-bib-0002"},{"key":"2024031418592112100_jbmr4049-bib-0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMms2009984","article-title":"The untold toll\u2014the pandemic's effect on patients without Covid-19","author":"Rosenbaum","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"2024031418592112100_jbmr4049-bib-0004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res."},{"key":"2024031418592112100_jbmr4049-bib-0005"},{"issue":"24","key":"2024031418592112100_jbmr4049-bib-0006","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures","volume":"319","author":"US Preventive Services Task Force Recommendation Statement","year":"2018","journal-title":"JAMA."},{"issue":"5","key":"2024031418592112100_jbmr4049-bib-0007","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","article-title":"FRAX and its applications to clinical practice","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone."},{"issue":"18","key":"2024031418592112100_jbmr4049-bib-0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"issue":"7","key":"2024031418592112100_jbmr4049-bib-0009","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024031418592112100_jbmr4049-bib-0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-014-2903-2","article-title":"Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized control trials","volume":"26","author":"Li","year":"2015","journal-title":"Osteoporosis Int."},{"key":"2024031418592112100_jbmr4049-bib-0011","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25829","article-title":"Hematological findings and complications of COVID-19","author":"Terpos","year":"2020","journal-title":"Am J Hematol."},{"key":"2024031418592112100_jbmr4049-bib-0012","doi-asserted-by":"crossref","DOI":"10.1055\/s-0040-1714350","article-title":"COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure","author":"Spiezia","year":"2020","journal-title":"Thromb Haemost."},{"issue":"7","key":"2024031418592112100_jbmr4049-bib-0013","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4158\/EP171828.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause: 2017 update","volume":"23","author":"Cobin","year":"2017","journal-title":"Endocr Pract."},{"issue":"8","key":"2024031418592112100_jbmr4049-bib-0014","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/s-0032-1328883","article-title":"The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis","volume":"38","author":"Artero","year":"2012","journal-title":"Semin Thromb Hemost."},{"issue":"7","key":"2024031418592112100_jbmr4049-bib-0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10\u2009years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2024031418592112100_jbmr4049-bib-0016","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"2024031418592112100_jbmr4049-bib-0017","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.39075","article-title":"Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"2024031418592112100_jbmr4049-bib-0018","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3899\/jrheum.161270","article-title":"Occurrence of serious infection in patients with rheumatoid arthritis treated with biologics and denosumab observed in a clinical setting","volume":"45","author":"Lau","year":"2018","journal-title":"J Rheumatol."},{"issue":"1","key":"2024031418592112100_jbmr4049-bib-0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"2024031418592112100_jbmr4049-bib-0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer."},{"issue":"4","key":"2024031418592112100_jbmr4049-bib-0021","first-page":"1492","article-title":"Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate osteoporosis prevention study group","volume":"85","author":"Ravn","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2024031418592112100_jbmr4049-bib-0022","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1210\/jc.2011-0412","article-title":"Effect of stopping risedronate after long-term treatment on bone turnover","volume":"96","author":"Eastell","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024031418592112100_jbmr4049-bib-0023","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6\u2009years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024031418592112100_jbmr4049-bib-0024","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/jbm.a.31599","article-title":"Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro","volume":"85","author":"Henneman","year":"2008","journal-title":"J Biomed Mater Res A."},{"issue":"3","key":"2024031418592112100_jbmr4049-bib-0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-007-0460-7","article-title":"Fracture risk remains reduced one year after discontinuation of risedronate","volume":"19","author":"Watts","year":"2008","journal-title":"Osteoporos Int."},{"issue":"5","key":"2024031418592112100_jbmr4049-bib-0026","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"25","key":"2024031418592112100_jbmr4049-bib-0027","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2024031418592112100_jbmr4049-bib-0028","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate\u2014results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone."},{"issue":"4","key":"2024031418592112100_jbmr4049-bib-0029","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1210\/clinem\/dgaa062","article-title":"Ten years of very infrequent zoledronate therapy in older women: an open-label extension of a randomized trial","volume":"105","author":"Grey","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024031418592112100_jbmr4049-bib-0030","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024031418592112100_jbmr4049-bib-0031","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024031418592112100_jbmr4049-bib-0032","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024031418592112100_jbmr4049-bib-0033","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"2024031418592112100_jbmr4049-bib-0034","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int."},{"key":"2024031418592112100_jbmr4049-bib-0035","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2024031418592112100_jbmr4049-bib-0036","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","article-title":"Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports","volume":"30","author":"Lamy","year":"2019","journal-title":"Osteoporos Int."},{"issue":"12","key":"2024031418592112100_jbmr4049-bib-0037","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2024031418592112100_jbmr4049-bib-0038","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int."},{"key":"2024031418592112100_jbmr4049-bib-0039","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res."},{"key":"2024031418592112100_jbmr4049-bib-0040","first-page":"S259","article-title":"Assessment of the effects of sequential treatment after discontinuing denosumab in 64 patients with postmenopausal osteoporosis","volume":"S1","author":"Ebina","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2024031418592112100_jbmr4049-bib-0041","first-page":"5432751","article-title":"Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation","volume":"17","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Case Rep Rheumatol."},{"issue":"9999","key":"2024031418592112100_jbmr4049-bib-0042","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet."},{"issue":"12","key":"2024031418592112100_jbmr4049-bib-0043","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024031418592112100_jbmr4049-bib-0044","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/14740338.1.1.71","article-title":"The gastrointestinal tolerability and safety of oral bisphosphonates","volume":"1","author":"Marschall","year":"2002","journal-title":"Expert Opin Drug Saf."},{"issue":"1","key":"2024031418592112100_jbmr4049-bib-0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2006.01.011","article-title":"Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety","volume":"54","author":"Epstein","year":"2006","journal-title":"Maturitas."},{"issue":"8","key":"2024031418592112100_jbmr4049-bib-0046","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"19","key":"2024031418592112100_jbmr4049-bib-0047","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"issue":"18","key":"2024031418592112100_jbmr4049-bib-0048","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med."},{"issue":"6","key":"2024031418592112100_jbmr4049-bib-0049","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2024031418592112100_jbmr4049-bib-0050","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos Int."},{"issue":"6","key":"2024031418592112100_jbmr4049-bib-0051","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med."},{"issue":"7","key":"2024031418592112100_jbmr4049-bib-0052","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1210\/jc.2015-1715","article-title":"Daily or cyclical teriparatide treatment in women with osteoporosis on no prior therapy and women on alendronate","volume":"100","author":"Cosman","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"2024031418592112100_jbmr4049-bib-0053","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bone.2018.10.020","article-title":"Administration of teriparatide for four years cyclically compared to two years daily in treatment-naive and alendronate treated women","volume":"120","author":"Cosman","year":"2019","journal-title":"Bone."},{"issue":"3","key":"2024031418592112100_jbmr4049-bib-0054","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2024031418592112100_jbmr4049-bib-0055","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2024031418592112100_jbmr4049-bib-0056","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2024031418592112100_jbmr4049-bib-0057","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/jbmr.3848","article-title":"Fracture and bone mineral density response by baseline risk in patients treated with abaloparatide followed by alendronate: results from the phase 3 ACTIVExtend trial","volume":"34","author":"Leder","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024031418592112100_jbmr4049-bib-0058","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel groups study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"16","key":"2024031418592112100_jbmr4049-bib-0059","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"15","key":"2024031418592112100_jbmr4049-bib-0060","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"issue":"10102","key":"2024031418592112100_jbmr4049-bib-0061","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet."},{"key":"2024031418592112100_jbmr4049-bib-0062","author":"Ferguson"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.4049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/6\/1009\/55453761\/jbmr4049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/35\/6\/1009\/55453761\/jbmr4049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T19:05:27Z","timestamp":1710443127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/35\/6\/1009\/7516486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,5,14]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4049","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"2020-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}